Atara Biotherapeutics, headquartered in Thousand Oaks, California, is a biotechnology company specializing in allogeneic T-cell immunotherapy, with products like Ebvallo and ATA3219 in various development stages. The company went public on October 16, 2014, and employs 173 staff.
Eric J Hyllengren sold 1,364 shares of ATRA on 18 November at $11.20 per share, worth a total of $15K. They now own 23,392 ATRA shares, or a 6% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
